FindTrial
Sign In

Fingolimod 1.25 mg

DRUG3 trials

Sponsors

Novartis

Conditions

Multiple SclerosisRelapsing-remitting Multiple Sclerosis

Phase 3

Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
CompletedNCT00289978
NovartisRelapsing-remitting Multiple Sclerosis
Start: 2006-01-31End: 2009-07-31Updated: 2012-04-11
Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase
CompletedNCT00340834
NovartisMultiple Sclerosis
Start: 2006-05-31End: 2011-07-31Updated: 2017-09-21
Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
CompletedNCT00662649
NovartisMultiple Sclerosis
Start: 2008-02-29End: 2011-06-30Updated: 2012-07-12

Related Papers

Safety and tolerability of conversion to siponimod from other disease-modifying therapies in patients with advancing forms of relapsing MS: Results from the EXCHANGE study
Multiple Sclerosis Journal2025-04-18
Group sequential methods for the Mann-Whitney parameter
Statistical Methods in Medical Research2022-06-139 citations
Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.
2016-11-1029 citations
Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.
2016-11-0326 citations
Teriflunomide Exhibits Similar Results to Fingolimod in Number Needed to Treat Analysis (P6.171)
Neurology2016-04-05
Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis.
2015-08-2023 citations
Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study
Journal of Neurology Neurosurgery & Psychiatry2015-06-25163 citations
Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS).
2013-12-1210 citations
Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study
Multiple Sclerosis and Related Disorders2013-11-0513 citations
Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.
2012-10-0185 citations
Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
2012-04-10120 citations
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
2011-05-13153 citations
Interpreting scores on multiple sclerosis-specific patient reported outcome measures (the PRIMUS and U-FIS).
2010-10-1117 citations
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
2010-01-201857 citations
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
2010-01-201547 citations